Life sciences firm LabCorp has entered a strategic collaboration with clinical laboratory testing services company Unilabs to enhance development and delivery of companion diagnostics globally for improving precision medicine.

The partners will expand the network of laboratories that help biopharmaceutical organisations in developing and commercialising these diagnostics.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In addition, commercialisation access will be enhanced in North America and Europe, with focus on diagnostics developed, as well as validated by LabCorp and its drug development unit Covance.

“The companies also intend to simplify technical, regulatory and clinical complications related to the assays using globally harmonised processes, which will initially be applied for oncology.”

LabCorp chairman and CEO David King said: “Companion diagnostics are an essential component of precision medicine, enabling physicians to identify the patients who are most likely to benefit from targeted and novel therapies.

“With this collaboration, we are capitalising on the scientific and operational strengths of two leaders in companion diagnostics to benefit biopharmaceutical clients who need global solutions for precision medicine, with the ultimate goal of improving health and improving lives for patients around the world.”

The companies also intend to simplify technical, regulatory and clinical complications related to the assays using globally harmonised processes, which will initially be applied for oncology.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Unilabs CEO Jos Lamers said: “Our collaboration with LabCorp addresses the need for global harmonisation and combined capabilities, including scientific expertise, operational excellence and timely availability of high-quality companion diagnostic services.

“Our combined ability to bridge the time gaps between development phase and drug approval, and to national reimbursement, by offering a centralized laboratory testing facility, gives our respective customers the advantage of early adoption of their drug.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact